Bal Pharma share news, announcements and annual reports
NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap
Bal Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, May 2006 on NSE
Last close ₹81.85down ₹2.76 (3.26%)BSE ₹81.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹84.61.
30 Oct: open ₹84.05, high ₹84.05, low ₹81.21
52-week range of traded prices to 30 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹130 Cr2,779th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 18.08
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.94
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,401
Bal Pharma results
77 filed, newest first. Page 2 of 2.
May 2016
Feb 2016
Nov 2015
Aug 2015
May 2015
Feb 2015
Nov 2014
Aug 2014
May 2014
29 May · Results
Feb 2014
12 Feb · Results
Nov 2013
12 Nov · Results
Aug 2013
May 2013
27 May · Results
Feb 2013
Nov 2012
Aug 2012
10 Aug · Results
10 Aug · Results
May 2012
11 May · Results
Feb 2012
Nov 2011
May 2011
5 May · Results
Bal Pharma Limited had informed the Exchange regarding a Board meeting to be held on May 13, 2011 to consider, and take on record, the Audited Financial Results of the Company (Instead of 4th quarter unaudited Financial Results) for the entire financial year ended on March 31, 2011. The Company has now informed the Exchange that due to unavoidable reasons, it has been decided to place, instead of audited accounts, unaudited accounts of the Company for the 4th quarter ended on March 31, 2011 before the meeting of the Board of Directors of the Company and publish the same on or before May 15, 2011.
Jan 2011
Nov 2010
Apr 2009
3 Apr · Results
We propose to consider the Audited Financial Results for the year and quarter ended on March 31, 2009 and will publish the Audited results on or before June 30, 2009. Therefore we will not be publishing unaudited results before April 30, 2009.
Apr 2008
7 Apr · Results
Management of the Company has decided to place audited accounts of the Company, instead of the unaudited financial results of the quarter, ended on , March 31, 2008, on or before June 30, 2008. The Company closes its financial year on March 31, 2008.
May 2007
24 May · Results
Company shall publish Audited Financial Results within a period of 3 month for the year ended on March 31, 2007 i.e. on or before June 30, 2007.